These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33130181)

  • 1. Assessment of outcomes of calciphylaxis.
    Gabel CK; Nguyen ED; Chakrala T; Blum AE; François J; Chand S; Rrapi R; Baker O; Dobry AS; Garza-Mayers AC; Ko LN; Shah R; St John J; Nigwekar SU; Kroshinsky D
    J Am Acad Dermatol; 2021 Oct; 85(4):1057-1064. PubMed ID: 33130181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical mimickers of calciphylaxis: A retrospective study.
    Gabel CK; Blum AE; François J; Chakrala T; Dobry AS; Garza-Mayers AC; Ko LN; Nguyen ED; Shah R; John JS; Nigwekar SU; Kroshinsky D
    J Am Acad Dermatol; 2021 Dec; 85(6):1520-1527. PubMed ID: 33744358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin-Associated Nonuremic Calciphylaxis.
    Yu WY; Bhutani T; Kornik R; Pincus LB; Mauro T; Rosenblum MD; Fox LP
    JAMA Dermatol; 2017 Mar; 153(3):309-314. PubMed ID: 28099971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.
    Santos PW; He J; Tuffaha A; Wetmore JB
    Int Urol Nephrol; 2017 Dec; 49(12):2247-2256. PubMed ID: 29058165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penile calciphylaxis: A retrospective case-control study.
    Gabel C; Chakrala T; Shah R; Danesh MJ; Dobry AS; Garza-Mayers AC; Ko LN; Nguyen E; St John J; Walls AC; Nigwekar SU; Song PI; Kroshinsky D
    J Am Acad Dermatol; 2021 Nov; 85(5):1209-1217. PubMed ID: 32422224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Uremic calciphylaxis].
    Lionet A; Urena Torres PA
    Nephrol Ther; 2022 Jun; 18(3):180-188. PubMed ID: 35514006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calciphylaxis: Controversies in Pathogenesis, Diagnosis and Treatment.
    Jeong HS; Dominguez AR
    Am J Med Sci; 2016 Feb; 351(2):217-27. PubMed ID: 26897281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Hypercoagulable Conditions and Calciphylaxis in Patients With Renal Disease: A Case-Control Study.
    Dobry AS; Ko LN; St John J; Sloan JM; Nigwekar S; Kroshinsky D
    JAMA Dermatol; 2018 Feb; 154(2):182-187. PubMed ID: 29238798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical Warfarin-Induced Calciphylaxis Outside a Typical Presentation of End-Stage Renal Disease on Hemodialysis.
    Licata T; Elliot J; Trecartin R; Clements A
    WMJ; 2023 Mar; 122(1):60-62. PubMed ID: 36940125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis.
    McCarthy JT; El-Azhary RA; Patzelt MT; Weaver AL; Albright RC; Bridges AD; Claus PL; Davis MD; Dillon JJ; El-Zoghby ZM; Hickson LJ; Kumar R; McBane RD; McCarthy-Fruin KA; McEvoy MT; Pittelkow MR; Wetter DA; Williams AW
    Mayo Clin Proc; 2016 Oct; 91(10):1384-1394. PubMed ID: 27712637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcific uremic arteriolopathy (calciphylaxis) calls into question the validity of guidelines of diagnosis and treatment.
    Chiriac A; Grosu OM; Terinte C; Perţea M
    J Dermatolog Treat; 2020 Aug; 31(5):545-548. PubMed ID: 31075991
    [No Abstract]   [Full Text] [Related]  

  • 12. [Calciphylaxis].
    Raimondi N; Del Vecchio JJ; Ghioldi M; Uzair E
    Medicina (B Aires); 2017; 77(4):331-333. PubMed ID: 28825580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Calciphylaxis: an enigma to the nephrologist].
    Barbera V; Di Lullo L; Otranto G; Barbera G; Santoboni A
    G Ital Nefrol; 2012; 29(6):674-82. PubMed ID: 23229665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calciphylaxis: risk factors, diagnosis, and treatment.
    Nigwekar SU; Kroshinsky D; Nazarian RM; Goverman J; Malhotra R; Jackson VA; Kamdar MM; Steele DJ; Thadhani RI
    Am J Kidney Dis; 2015 Jul; 66(1):133-46. PubMed ID: 25960299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calciphylaxis: natural history, risk factor analysis, and outcome.
    Weenig RH; Sewell LD; Davis MD; McCarthy JT; Pittelkow MR
    J Am Acad Dermatol; 2007 Apr; 56(4):569-79. PubMed ID: 17141359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penile calciphylaxis: analysis of risk factors and mortality.
    Karpman E; Das S; Kurzrock EA
    J Urol; 2003 Jun; 169(6):2206-9. PubMed ID: 12771751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Cutaneous Calciphylaxis.
    Kodumudi V; Jeha GM; Mydlo N; Kaye AD
    Adv Ther; 2020 Dec; 37(12):4797-4807. PubMed ID: 32997277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis.
    Ruderman I; Toussaint ND; Hawley CM; Krishnasamy R; Pedagogos E; Lioufas N; Elder GJ
    Nephrol Dial Transplant; 2021 Mar; 36(4):649-656. PubMed ID: 31855262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case-control study of calciphylaxis in Japanese end-stage renal disease patients.
    Hayashi M; Takamatsu I; Kanno Y; Yoshida T; Abe T; Sato Y;
    Nephrol Dial Transplant; 2012 Apr; 27(4):1580-4. PubMed ID: 22121234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: update on the management of calciphylaxis.
    Seethapathy H; Brandenburg VM; Sinha S; El-Azhary RA; Nigwekar SU
    QJM; 2019 Jan; 112(1):29-34. PubMed ID: 30304522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.